Q2 25 EPS
$-0.19
BEAT +38.71%
Est. $-0.31
Q2 25 Revenue
$631.9M
BEAT +1.46%
Est. $622.8M
vs S&P Since Q2 25
-15.4%
TRAILING MARKET
TDOC +0.1% vs S&P +15.6%
Market Reaction
Did TDOC Beat Earnings? Q2 2025 Results
Teladoc Health delivered a cleaner-than-expected second quarter, posting a loss of $0.19 per share against a consensus estimate of $0.31, a beat of 38.71%, while revenue of $631.90 million edged past the $622.80 million estimate by 1.46%, though it s… Read more Teladoc Health delivered a cleaner-than-expected second quarter, posting a loss of $0.19 per share against a consensus estimate of $0.31, a beat of 38.71%, while revenue of $631.90 million edged past the $622.80 million estimate by 1.46%, though it still fell 1.6% from a year ago. The headline improvement was driven largely by a dramatic narrowing of the net loss to $32.66 million, compared with $837.67 million in Q2 2024, a period that had been heavily distorted by a $790.00 million non-cash goodwill impairment charge. Beneath the surface, however, the company's two segments told diverging stories: Integrated Care grew revenue 4% to $391.51 million, while BetterHelp continued to shrink, declining 9% to $240.39 million as paying users fell 5% to 388,000. Despite the earnings beat, shares sold off sharply in after-hours trading, reflecting investor unease about the growth trajectory. For full-year 2025, Teladoc guided revenue of $2.50 billion to $2.55 billion, with BetterHelp expected to remain in decline and free cash flow targeted at $170.00 million to $200.00 million.
Key Takeaways
- • Integrated Care segment revenue growth of 4% driven by 11% increase in U.S. Integrated Care members to 102.4 million
- • Other revenue increased 31% year-over-year to $108.2 million
- • International revenue grew 10% to $112.2 million
- • Net loss dramatically reduced from $837.7 million to $32.7 million due to absence of prior-year $790 million goodwill impairment charge
- • BetterHelp paying users declined 5% to 388,000, driving 9% revenue decline
TDOC YoY Financials
Q2 2025 vs Q2 2024, source: SEC Filings
TDOC Revenue by Segment
With YoY comparisons, source: SEC Filings
TDOC Revenue by Geography
With YoY comparisons, source: SEC Filings
“I'm pleased with our performance in the second quarter, with consolidated revenue and adjusted EBITDA both at the higher end of our guidance ranges. This reflects continued disciplined execution and builds on our solid results from the first quarter. We continue to work with focus and urgency to advance our strategic priorities, invest in products and capabilities, and deliver solid financial performance.”
— Chuck Divita, Q2 2025 Earnings Press Release
TDOC Earnings Trends
TDOC vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
TDOC EPS Trend
Earnings per share: estimate vs actual
TDOC Revenue Trend
Quarterly revenue: estimate vs actual
TDOC Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 | — | — | — | — | — |
| Q4 25 BEAT FY | $-0.22 | $-0.14 | +35.19% | $642.3M | +1.09% |
| FY Full Year | $-0.99 | $-1.14 | -14.92% | $2.53B | +0.27% |
| Q3 25 BEAT | $-0.31 | $-0.28 | +8.94% | $626.4M | +0.06% |
| Q2 25 BEAT | $-0.31 | $-0.19 | +38.71% | $631.9M | +1.46% |
| Q1 25 MISS | $-0.36 | $-0.53 | -48.04% | $629.4M | +1.64% |